5 Top NASDAQ Biotech Stocks: AVEO Pharmaceuticals Gained 63.66 percent

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 9.57 percent increase over the last five trading days and ended the week at 3,354.13 points. The Index is down 20.97 percent year-to-date.
Last week the US Senate unveiled a first look at the much debated healthcare replacement bill, according to multiple reports the bill would stop the expansion of Medicaid in 2021 and strip the program’s budget. “This program has provided coverage to more Americans than the private marketplaces,” Vox reported. The Investing News reported on a EY biotech market report that indicated despite the political turmoil, 2017 has been a good year for the industry and is poised to keep growing. Bluebird Bio released impressive data on genetic therapy treating inherited blood disorders.

• AVEO Pharmaceuticals (NASDAQ:AVEO)
• BioDelivery Sciences (NASDAQ:BDSI)
• Dynavax Technologies (NASDAQ:DVAX)
• Catalyst Pharmaceutical (NASDAQ:CPRX)
• Ekso Bionics Holdings (NASDAQ:EKSO)

AVEO Pharmaceuticals

This pharmaceutical is working on cancer candidate treatments. AVEO saw a push in its stock due to getting closer to receiving European approval for their kidney cancer drug.
AVEO Pharmaceuticals gained 63.66 percent last week to finish at $1.25 per share.

BioDelivery Sciences

BDSI is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. Last week the company announced it had received approval from Health Canada for BELBUCA, BDSI buprenorphine hydrochloride buccal film for the management of pain. Related to the company’s products they also announced an agreement with CVS/Caremark until 2020.
BioDelivery Sciences gained 22.26 percent last week to finish at $2.95 per share.

Dynavax Technologies

This clinical-stage immunotherapy company has product candidates currently being investigated for use in cancer, as a hepatitis B vaccine and modifying therapy for asthma. On June 2, the company showcased new findings from their Phase 1b/2 study for SD-101.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Dynavax Technologies gained 26.75 percent last week to finish at $9.95 per share.

Catalyst Pharmaceutical

This pharmaceutical company is focused on developing and commercializing therapies for people with rare diseases. They currently have three drug candidates for the treatments of lambert-eaton myasthenic syndrome and congenital myasthenic syndromes. One June 1 the company announced it would present them at the Jefferies 2017 Healthcare Conference, which took place on June 6.
There has been no further recent news from the company to explain last week’s rise in share price.
Catalyst Pharmaceutical gained 22.94 percent last week to finish at $2.84 per share.

Ekso Bionics Holdings

Despite falling down to the bottom of the list, Ekso makes an appearance on the top gainers list for a second week in a row. This company develops exoskeletons for people involved in the medical, industrial and defense fields. One June 15 the company announced it would be collaborating with four rehab facilities to establish Centers of Robotic Excellence in order to support the use of exoskeleton technology for mobility impaired patients.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Ekso Bionics Holdings gained 22.40 percent last week to finish at $2.35 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
 

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.49 percent decrease over the last five trading days and ended the week at 3,076.15 points. The Index is down 10.4 percent year-to-date.
Last week Investing News Network (INN) reported on the FDA’s decision to ask Endo Pharmaceuticals (NASDAQ:ENDP) to remove its opioid-based product Opana ER, with a warning that it could remove its approval. Newly appointed FDA commissioner Scott Gottlieb asked for public input when it comes to the current opioid crisis impacting the US. A group of US Senators is banding together to introduce a bill that would protect medical marijuana all over the country, potentially ending the conflict between states and the federal power in the US.

• Ekso Bionics Holdings (NASDAQ:EKSO)
• GTx (NASDAQ:GTXI)
• Sorrento Therapeutics (NASDAQ:SRNE)
• Adamis Pharmaceuticals (NASDAQ:ADMP)
• EDAP TMS SA (NASDAQ:VYGR)

Ekso Bionics Holdings

Ekso is a developer of exoskeletons for people involved in the medical, industrial and defense fields. On June 5 the company revealed it had completed the development of a new exoskeleton prototype called Artemis, a lighter design which only weighs 13 pounds.
Ekso Bionics Holdings gained 57.38 percent last week to finish at $1.92 per share.

GTx

GTx is a company focused on the discovery, development and commercialization of small molecules for the treatment of cancer. Last week the company shared positive data from its ongoing Phase 2 proof-of-concept clinical trial of enobosarm 3 mg (GTx-024) in postmenopausal women with stress urinary incontinence.
GTx gained 49.19 percent last week to finish at $4.61 per share.

Sorrento Therapeutics

Sorrento is a biopharmaceutical working on drug therapies in the oncology field. The company saw a clear up last week as all the lawsuits from Wildcat Liquid Alpha against the company were dismissed. Sorrento also shared positive data from its subsidiary SCILEX Pharmaceutical study with its lead product ZTlido.
Sorrento Therapeutics gained 29.03 percent last week to finish at $2 per share.

Adamis Pharmaceuticals

Adamis is a pharmaceutical company engaged in the development of products treating allergies and in the respiratory market. Last week the company obtained approval from the US Food and Drug Administration for its epinephrine pre-filled syringe –Symjepi– a direct rival to the widely used and criticized EpiPen.
Adamis Pharmaceuticals gained 20.93 percent last week to finish at $5.20 per share.

EDAP TMS SA

Making its second week in a row appearance on the roundup EDAP TMS SA is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. Positive earnings estimates have made the rounds online. However, there has been no further recent news from the company to explain last week’s rise in share price.
EDAP TMS SA gained 14.38 percent last week to finish at $3.66 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.67 percent decrease over the last five trading days and ended the week at 3,076.15 points. The Index is up 10.94 percent year-to-date.
Last week the FDA requested Endo Pharmaceutical (NASDAQ:ENDP) to remove their opioid-based product Opana ER, due to the crisis in the US, the announcement was prefaced by a board ruling. FierceBiotech reported Mathai Mammen is jumping ships from Merck (NYSE: MRK) and joining the research and development team at Johnson & Johnson (NYSE:JNJ).

• Dynavax Technologies (NASDAQ:DVAX)
• EDAP TMS SA (NASDAQ:EDAP)
• Fortress Biotech (NASDAQ:FBIO)
• Antares Pharma (NASDAQ:ATRS)
• Collegium Pharmaceutical (NASDAQ:COLL)

Dynavax Technologies

This clinical-stage immunotherapy company has product candidates currently being investigated for use in cancer, as a hepatitis B vaccine and modifying therapy for asthma. On June 2, the company showcased new findings from their Phase 1b/2 study for SD-101.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Dynavax Technologies gained 22.03 percent last week to finish at $7.20 per share.

EDAP TMS

EDAP is a is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. On May 22, the company announced the Centers for Medicare and Medicaid Services “established a new billing code for HIFU ablation of prostate tissue.”
EDAP TMS SA gained 19.85 percent last week to finish at $3.20 per share.

Fortress Biotech

This biopharmaceutical company is working on treatments for autoimmune diseases and cancer. Last week the company one of the company’s subsidiaries Mustang Bio, entered an exclusive licensing agreement with City of Hope for three novel CAR T therapies, which will be used for cancer treatments.
Fortress Biotech gained 10.20 percent last week to finish at $4.43 per share.

Antares Pharma

Antares is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Last week the company revealed it entered into a loan and security agreement for a $35 million term loan with Hercules Capital.
Antares Pharma gained 10.12 percent last week to finish at $2.83 per share.

Collegium Pharmaceutical

This specialty pharmaceutical company is developing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. One June 1, the company announced it will present new data on its product Xtampza ER at this year’s International Conference on Opioids.
Collegium Pharmaceutical gained 9.97 percent last week to finish at $10.48 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
 

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 1.85 percent increase over the last five trading days and ended the week at 3,017.07 points. The Index is up 11.69 percent year-to-date.
The past week saw BioNap writing on HedgePath Pharmaceuticals (OTCMKTS: HPPI) their meeting with the US Food and Drug Administration regarding the results from a Phase 2b clinical study of SUBA-Cap. BriaCell announced it dosed the second patient for their Phase 1/2a clinical study of BriaVax. FierceBiotech reported that Gur Roshwalb, the CEO of Akari Therapeutics (NASDAQ:AKTX) resigned following the revelation that he “contravened company policy and found an Akari statement falsely claimed a patient met the primary endpoint in a phase 2 trial.” STAT News reported on the “tragic” deaths of 15 children in South Sudan, who according to the World Health Organization died due to a “botched measles vaccination campaign.”

• Neuralstem (NASDAQ:CUR)
• Microbot Medical (NASDAQ:MBOT)
• Adamis Pharmaceuticals (NASDAQ:ADMP)
• Albireo Pharma (NASDAQ:ALBO)
• Cytrx (NASDAQ:CYTR)

Neuralstem

This clinical-stage biopharmaceutical company is working on therapies for the nervous system on its human neuronal stem cells and its stem-cell derived small molecule compounds. On May 17 the company announced it completed dosing the last patient for a phase 2 clinical trial and anticipated the data to be ready during the third quarter of 2017.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Neuralstem gained 25.06 percent last week to finish at $5.19 per share.

Microbot Medical

Microbot is a medical device company developing micro-robotic tech in the medical landscape. The company has two product candidates. Last week the company announced it obtained a patent for the company’s Self-Cleaning Shunt from the Canadian Intellectual Property Office.
Microbot Medical gained 24.10 percent last week to finish at $3.81 per share.

Adamis Pharmaceuticals

This company has a variety of allergy and respiratory products, their pharmaceutical portfolio includes the Epinephrine pre-filled syringe. On April 26 the company completed a public offering of  approximately $17,250,000.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Adamis Pharmaceuticals gained 22.97 percent last week to finish at $4.55 per share.

Albireo Pharma

Albireo is a clinical-stage biopharmaceutical working on the development of bile acid modulators to treat orphan pediatric liver diseases. Last week the company closed a public offering which will result in approximately $48.2 million net proceeds.
Albireo Pharma gained 13.61 percent last week to finish at $20.37 per share.

Cytrx

Cytrx is focused on the clinical development of aldoxorubicin and is currently performing phase 3 trials on the drug as therapy for patients with soft tissue sarcoma. On May 17 the company revealed it would be presenting new updates on the status of current trials in their pipeline at the American Society of Clinical Oncology annual meeting.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Cytrx gained 12.33 percent last week to finish at $0.82 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
 

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.74 percent percent decrease over the last five trading days and ended the week at 3,017.07 points. The Index is up 8.81 percent year-to-date.
Last week the Congressional Budget Office revealed the GOP replacement to Obamacare would end up nixing insurance coverage to 26 million american citizens by 2026 in an attempt to reduce $119 billion over the next decade. FDA head Scott Gottlieb announced it would remove the federal hiring freeze to his agency.

• Nutraceutical (NASDAQ:NUTR)
• CytRx (NASDAQ:CYTR)
• MannKind (NASDAQ:MNKD)
• MEI Pharma (NASDAQ:MEIP)
• Sinovac Biotech (NASDAQ:SVA)

Nutraceutical

This company is an integrated manufacturer, marketer, distributor and retailer of nutritional supplements and other natural products. Last week the company revealed it was being acquired by an affiliate of HGGC.
“Nutraceutical stockholders will receive $41.80 in cash (without interest) for each outstanding share of Nutraceutical,” said the statement from the company.
Nutraceutical gained 48.93 percent last week to finish at $41.70 per share.

CytRx

This is a biopharmaceutical company researching oncology methods and therapies including the clinical development of aldoxorubicin, a modified version of the chemotherapeutic agent doxorubicin. On May 17 the company announced it would be presenting new research data at the 2017 American Society of Clinical Oncology annual meeting. However, there has been no further recent news from the company to explain last week’s rise in share price.
CytRx gained 40.52 percent last week to finish at $0.73 per share.

MannKind

This pharmaceutical company works on developing therapeutic products for diabetes and other diseases. On May 10 the company released their financial report for the first quarter of 2017. However, there has been no further recent news from the company to explain last week’s rise in share price.
MannKind gained 34.51 percent last week to finish at $1.52 per share.

MEI Pharma

MEI is a company working on anti-cancer drugs and therapies. On May 18 the company announced in coordination with Helsinn Group, it would present new data on gene mutation and clinical findings from a recent study. However, there has been no further recent news from the company to explain last week’s rise in share price.
MEI Pharma gained 30.86 percent last week to finish at $2.12 per share.

Sinovac Biotech

This biopharmaceutical is focused on developing vaccines, which target infectious diseases like influenza. On May 16 the company delayed their annual report and announced it received a “written notice” from the NASDAQ listing qualifications department.
Sinovac Biotech gained 13.36 percent last week to finish at $5.26 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.83 percent decrease over the last five trading days and ended the week at 3,039.46 points. The Index is up 9.62 percent year-to-date.
Last week the Congressional Budget Office revealed it would be sharing the official score of the GOP’s recently passed healthcare bill this week, the lack of this score was a big criticism of the bill passed by Congress. New FDA head Scott Gottlieb gave his first speech to the agency as his duties commence, he pointed to the opioid crisis as one of the biggest challenges facing the agency. We interviewed Paul Gudonis, CEO of Myomo a company in the process of an IPO about their product the mechanical arm MyoPro, which helps people who have lost control of their limbs.

• Nature’s Sunshine Products (NASDAQ:NATR)
• BioDelivery Sciences Intl. (NASDAQ:BDSI)
• Immunogen Inc. (NASDAQ:IMGN)
• AVEO Pharmaceuticals (NASDAQ:AVEO)
• Alnylam Pharmaceuticals (NASDAQ:ALNY)

Nature’s Sunshine Products

Nature’s Sunshine Products is engaged in the manufacturing and direct selling of nutritional and personal care products. The rise in stock was thanks to the announcement that the company received a selling license in China and will be able to enter the lucrative market.
“Having made significant investments over the last couple of years, building the infrastructure to support the commencement of operations, we are in a position to begin direct selling activities in the near-term,” Paul E. Noack, President of China and New Markets at Nature’s Sunshine Products said.
Nature’s Sunshine Products gained 31.40 percent last week to finish at $11.30 per share.

BioDelivery Sciences

BioDelivery Sciences is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. Last week the company shared its financial report for the first quarter of the year, with a net revenue of $9.5 million.
BioDelivery Sciences gained 28.95 percent last week to finish at $2.45 per share.

Immunogen

Immunogen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate technology. The company revealed it was moving forward with an experimental antibody-drug which shrinks or stabilizes tumors of advanced ovarian cancer patients.
Immunogen gained 28.05 percent last week to finish at $5.25 per share.

AVEO Pharmaceuticals

AVEO Pharmaceuticals is a biopharmaceutical working on drug candidates against cancer. Last week the company revealed it completed an explanation to the Committee for Medicinal Products for Human Use about using Tivozanib as a treatment for patients with first-line renal cell carcinoma.
AVEO Pharmaceuticals gained 26.37 percent last week to finish at $0.73 per share.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development, and commercialization of ribonucleic acid interference therapeutics. The company granted its new Chief Financial Officer Manmeet Soni stock options on May 12. However, there has been no further recent news from the company to explain last week’s rise in share price.
Alnylam Pharmaceuticals gained 26.25 percent last week to finish at $71.67 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 1.02 percent decrease over the last five trading days and ended the week at 3,064.87 points. The Index is up 10.54 percent year-to-date.
Last week the US Senate confirmed Scott Gottlieb as head of the US Food and Drug Administration. A new report on the pharma industry revealed, despite many pricing controversies last year, products in these sector continue to sell at high prices. STAT News reported on how the massive cyberattack from last week “crippled” hospital networks in the UK.

• Sangamo Therapeutics (NASDAQ:SGMO)
• Durect (NASDAQ:DRRX)
• Merus Labs International (NASDAQ:MSLI)
• MannKind (NASDAQ:MNKD)
• NantKwest (NASDAQ:NK)

Sangamo Therapeutics

Sangamo is a clinical-stage biotechnology company focused on working with genomic therapies like genome editing, gene therapy, gene regulation and cell therapy. Last week’s rise in Sangamo’s stock was due to the announcement of a partnership between the company and Pfzer (NASDAQ:) to develop and commercialize gene therapy program for Hemophilia A.
Sangamo also released their financial report for the second quarter of the year. “Three Phase 1/2 in vivo genome editing clinical trials are now screening subjects, and the fourth trial evaluating SB-525, a cDNA gene therapy approach for Hemophilia A, will open later this quarter,” Dr. Sandy Macrae, CEO of Sangamo, said in a statement.
Sangamo Therapeutics gained 80.22 percent last week to finish at $8.20 per share.

Durect

Durect is a biopharmaceutical company with two commercial products and an extensive pipeline of products, including two on at the NDA stage. Similarly to Sangamo, last week Durect released a set of financial results and a revealed $239 million development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE:NVS).
“Recent enrollment rates for PERSIST, the POSIMIR pivotal Phase 3 clinical trial in post-operative pain, are ahead of schedule and support completion of dosing in the second quarter of 2017,” said president and CEO of DURECT James E. Brown in a statement.
Durect gained 51.25 percent last week to finish at $1.21 per share.

Merus Labs International

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of branded prescription pharmaceutical products. Last week the company shared it had entered a definitive arrangement agreement with Norgine. In this deal Norgine will acquire all common shares of Merus for a total of approximately $342 million.
As part of a statement for their latest financial results report to investors, Barry Fishman CEO of Merus, said the company was on track to deliver on their plans for 2017. The company’s revenue saw an increase in revenue from last year’s second quarter total of 19.7 million to this year 22.6 million.
Merus Labs International gained 48.88 percent last week to finish at $1.18 per share.

MannKind

MannKind is a pharmaceutical company developing therapeutic products for diabetes and other diseases. The week started strong for the company seeing their highest trading day Wednesday May 10, where its stock closed at $1.60. Despite that later in the week the company released their financial results for the first quarter of the year, indicating a $16.3 million loss. With its lead product Afrezza producing $1.2 million in revenue.
The press release contained no statement from the company’s CEO and CFO Matthew J. Pfeffer.
MannKind gained 40.49 percent last week to finish at $1.12 per share.

NantKwest

NantKwest is a clinical-stage immunotherapy company working to treat cancer, infectious diseases and inflammatory diseases. Last week the company revealed it had received authorization from the US Food and Drug Administration.
NantKwest gained 35.84 percent last week to finish at $3.98 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.58 percent decrease over the last five trading days and ended the week at 3,096.41 points. The Index is up 11.67 percent year-to-date.
Last week House Republicans finally managed to pass a health care bill, that has caused outrage against it and the process behind the vote of it. Mexico voted on legalizing the use of cannabis for medical and scientific reasons, a move that could benefit Canadian companies looking to expand their business. FierceBiotech reported on Seattle Genetics’ (NASDAQ:SGEN) decision to scrap a deal with Immunomedics (NASDAQ:IMMU) due to the removal from the latter’s CEO Cynthia Sullivan. Following the vote on the new health care reforms, multiple reports of inside notes inside the bill like a defunding of the reproductive health care group Planned Parenthood and the removal of $1 billion from the Centers for Disease Control and Prevention budget.

• Span-America Medical Systems (NASDAQ:SPAN)
• Myriad Genetics (NASDAQ:MYGN)
• Concordia International (NASDAQ:CXRX)
• EXACT Sciences (NASDAQ:EXAS)
• ChromaDex Corporation (NASDAQ:CDXC)

Span-America Medical Systems

Span-America Medical Systems manufactures therapeutic equipment for the medical market like medical bed frames or wheelchair cushions. Last week the company presented their financials for the fiscal second quarter of 2017, revealing a sales increase of three percent to $15.2 million. The company also announced an acquisition deal, which would see it get absorbed by Savaria Corporation (TSX:SIS) for approximately $80.2 million.
Span-America Medical Systems gained 32.97 percent last week to finish at $28.96 per share.

Myriad Genetics

Myriad Genetics is a molecular diagnostic company working on the development of those same tests, these can look at the possibility of patients to develop various diseases at one point in their lives. The company revealed their financial numbers for the fiscal third quarter of 2017, which saw a total revenue of 196.9 million and an increase in their hereditary cancer testing.
Myriad will also be doing four presentations on prostate cancer at the annual meeting of the American Urological Association.
Myriad Genetics gained 21.70 percent last week to finish at $22.38 per share.

Concordia

Concordia is a pharmaceutical selling branded and generic prescription products and seeks on the acquisition, licensing and development of development in off-patent prescription medicines and orphan drugs.
Last week the company announced the appointment of two new board members this year. However, there has been no further recent news from the company to explain last week’s rise in share price.
Concordia International gained 19.44percent last week to finish at $1.51 per share.

EXACT Sciences

Staying strong after being featured in last week’s top gainers, EXACT works on the detection and prevention of various cancers through molecular diagnostics.
Last week analysts at Cowen Insight surveyed doctors in the area and concluded the company could reach a $700 million revenue mark in 2019 thanks to Cologuard, which uses feces to test for colon cancer.
EXACT Sciences gained 18.06 percent last week to finish at $35.43 per share.

Chroma Dex

Chroma Dex also managed to stay on the top gainers this week, albeit it went from first place to last. The company holds a portfolio of health products and supplements.
Last week the company announced it would be disclosing its financial results for the first quarter of 2017 on May 11. However, there has been no further recent news from the company to explain last week’s rise in share price.
ChromaDex gained 16.08 percent last week to finish at $3.61 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 3.5 percent increase over the last five trading days and ended the week at 3,114.67 points. The Index is up 12.33 percent year-to-date.
Last week the GOP failed again to bring a potentially viable health care bill onto the floor of Congress, the market has been settling into these weekly attempts and chatter of a re-introduction of an Obamacare replacement. The US Food and Drug Administration approved a new treatment for acute myeloid leukemia to Novartis Pharmaceuticals (VTX:NOVN). BioMarin Pharmaceutical (NASDAQ:BMRN) also received approval for a form of Batten disease treatment.

• ChromaDex Corporation (NASDAQ:CDXC)
• EXACT Sciences (NASDAQ:EXAS)
• Epizyme (NASDAQ:EPZM)
• Sangamo Therapeutics (NASDAQ:SGMO)
• LeMaitre Vascular (NASDAQ:LMAT)

ChromaDex Corporation

ChromaDex is a company looking to develop ingredient technologies for a variety of health improvements. They hold an extensive portfolio of health supplements and products. Last week the company announced the sale of up to $25 million in common stock to Hong Kong billionaire Li Ka-Shing.
ChromaDex gained 36.40 percent last week to finish at $3.11 per share.

EXACT Sciences

EXACT Sciences is a molecular diagnostics company, they work on detection and prevention of some types of cancer. The company revealed their financial results for the first quarter of the year last week, indicating a revenue stream of $48.4 million and the completion of 470,000 clonguard tests, the company’s colon cancer trial.
EXACT Sciences gained 25.41 percent last week to finish at $30.01 per share.

Epizyme

This clinical-stage biopharmaceutical is working on epigenetic therapies for cancer patients. The US Food and Drug Administration granted a Fast Track designation to tazemetostat treating lymphoma, meaning it may reduce development time and costs when bringing a drug to market.
Epizyme gained 24.05 percent last week to finish at $18.05 per share.

Sangamo Therapeutics

Sangamo is a clinical-stage biotechnology company using genetic therapy and has partnered to expedite clinical and commercial development. Last week the company announced it would be presenting at the American Society of Gene & Cell Therapy meeting. Their founder and chairman Edward Lanphier announced he would be retiring following a year-long transition process in the company. However, there has been no further recent news from the company to explain last week’s rise in share price.
Sangamo Therapeutics gained 18.52 percent last week to finish at $4.80 per share.

LeMaitre Vascular

LeMaitre is a medical device company working on peripheral vascular disease. Last week the company revealed their financials for the first quarter of the year, with it the announcement that revenue increases 19 percent to 24.1 million. While earnings per share went up 42 percent.
LeMaitre Vascular gained 18.34 percent last week to finish at $29.75 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went down 1.12 percent over the last five trading days and ended the week at 3,009.35 points. The Index is up 8.53 percent year-to-date.
Last week Jason Napodano from BioNap announced the launch of his new research service, in which he uses his 5 C’s method to evaluate life science companies, we interviewed Napodano a while ago about this novel concept and what to look for in companies. The Trump administration once again raised the potential for a new vote on healthcare reform as his first 100-day mark in the White House gets closer. Late last week Fiercebiotech reported on XBiotech likely getting rejected by the European Medicines Agency.
Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

• CytRx Corporation (NASDAQ:CYTR)
• Rockwell Medical Inc (NASDAQ:RMTI)
• ImmunoGen, Inc. (NASDAQ:IMGN)
• NewLink Genetics Corp (NASDAQ:NLNK)
• TearLab Corp (NASDAQ:TEAR)

CytRx Corporation

This specialty biopharmaceutical is targeting cancer therapies for patients with soft tissue sarcoma through aldoxorubicin. Last week the company revealed its lead candidate is closer to obtaining FDA approval while saying it is tentatively targeting Q4 to launch and NDA.
CytRx Corporation gained 40.82 percent last week to finish at $0.61 per share.

Rockwell Medical

Rockwell is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease. Their drug products include Triferic and Calcitriol. Last week the company announced the filing of definitive proxy materials with the SEC.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Rockwell Medical gained 33.28 percent last week to finish at $8.09 per share.

ImmunoGen

This clinical-stage biotechnology uses its antibody-drug conjugate technology to develop cancer therapies. Late last week the company announced a conference call for May 5, to discuss its upcoming Q1 2017 financial results.
According to The Motley Fool “an analyst at Leerink upgraded the biotech to outperform and slapped an $8 price target on the stock,” causing the increase. However, there has been no further recent news from the company to explain last week’s rise in share price.
ImmunoGen gained 24.38 percent last week to finish at $4.03 per share.

NewLink Genetics

NewLink is a clinical-stage company working on immunotherapeutic products for cancer treatment. The company announced the presentation of new data at the American Society of Clinical Oncology Annual Meeting in Chicago.
However, there has been no further recent news from the company to explain last week’s rise in share price.
NewLink Genetics Corp gained 16.65 percent last week to finish at $18.08 per share.

TearLab

This in-vitro diagnostic company has commercialized tear testing platform for sensitive and specific biomarkers in eye care. The last news from the company came in March as their announced their financial results for 2016 and its fourth quarter. In it, they reported revenue totaling $28 million.
However, there has been no further recent news from the company to explain last week’s rise in share price.
TearLab Corp gained 12.26 percent last week to finish at $2.38 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went up 0.12 percent over the last four trading days and ended the week at 3,043.38 points. The Index is up 9.76 percent year-to-date.
Last week we interviewed the CEO of Propanc Biopharma about their cancer technology. We also reported on OncoMed stumble as its key cancer trial got pulled. STAT News published a lenghty report on the severe case of yellow fever in Brazil.
Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

• Neurocrine Biosciences (NASDAQ:NBIX)
• Novelion Therapeutics (NASDAQ:NVLN)
• Akorn, Inc. (NASDAQ:AKRX)
• Galectin Therapeutics Inc. (NASDAQ:GALT)
• ZIOPHARM Oncology (NASDAQ:ZIOP)

Neurocrine Biosciences

Neurocrine received a boost thanks to the news that the FDA approved Ingrezza, the company’s drug for tardive dyskinesia which causes involuntary movements in the face. Neurocrine earned FDA approval without getting a black box warning on depression and suicide.
Neurocrine Biosciences gained 32.68 percent last week to finish at $53.39 per share.

Novelion Therapeutics

Novelion is a pharmaceutical company working on therapies for rare diseases. Recently the company presented new data on an open-label study for patients with partial lipodystrophy associated NASH, at the Annual Meeting of the Endocrine Society.
Novelion Therapeutics gained 31.03 percent last week to finish at $10.36 per share.

Akorn

Akorn makes it to the list of top gainers for two weeks in a row after talks about an acquisition from Fresenius Kabi, a subsidiary of Fresenius Medical Care (NYSE:FMS) have continued, with analysts even declaring it a potentially fairly positive move. All speculation still with no confirmation yet.
Akorn gained 28.55 percent last week to finish at $32.42 per share.

Galectin Therapeutics

Also repeating after being featured in last week’s roundup, Galectin seeks to create new therapies that will help patients with chronic liver, skin diseases, and cancer.
Last week the company indicated it received positivity from the FDA about its current Phase II trial of GR-MD-02 designed to treat patients with NASH cirrhosis.
Galectin Therapeutics gained 28.46 percent last week to finish at $3.16 per share.

ZIOPHARM Oncology

ZIOPHARM is focused on acquiring, developing and commercializing a portfolio of cancer therapies. Most recently, on April 3,  the company gave an update on its chimeric antigen receptor T cell therapy for cancer.
However, there has been no further recent news from the company to explain last week’s rise in share price.
ZIOPHARM Oncology gained 19.58 percent last week to finish at $7.33 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went down 0.95 percent over the last five trading days and ended the week at 3,073.92 points. The Index is up 9.63 percent year-to-date.
Last week the Investing News Network reported on the GOP and President Trump’s intentions to bring their health care bill back for a new vote. The potential nominee to head the FDA, Scott Gottlieb last week expressed his stance against anti-vaccine people. Last week GEN reported on a new discovery on sleep genes from scientists at Washington State University.

• Innocoll Holdings (NASDAQ:INNL)
• Galectin Therapeutics (NASDAQ:GALT)
• Akorn (NASDAQ:AKRX)
• Pluristem Therapeutics (NASDAQ:PSTI)
• Paratek Pharmaceuticals (NASDAQ:PRTK)

Here’s a closer look at those companies.

Innocoll Holdings

Innocoll is a commercial-stage pharmaceutical and medical device company set to develop its biodegradable and bioresorbable products and product candidates. Last week the company announced an agreement for Gurnet Point L.P. to acquire them, for an approximate $209 million in aggregate.
Innocoll Holdings gained 87.05 percent last week to finish at $2.10 per share.

Galectin Therapeutics

This biotechnology company seeks to create new therapies for patients with chronic liver, skin diseases, and cancer. Most recently Galectin presented their financial results for 2016, where it posted a net loss of $22.4 million. However, there has been no further recent news from the company to explain last week’s rise in share price.
Galectin Therapeutics gained 24.78 percent last week to finish at $2.87 per share.

Akorn

Akorn is a specialty generic pharmaceutical company developing, manufactures and markets generic and branded prescription pharmaceuticals. Shares of the company rose after a Bloomberg report, indicating Frenius SE (ETR:FRE) is considering a bid for the company.
Akorn gained 23.63 percent last week to finish at $29.77 per share.

Pluristem Therapeutics

This clinical-stage biotherapy company uses placenta-based cell therapy product candidates to treat ischemic, inflammatory and hematologic conditions.
Most recently the company announced it was in late conversations with Sosei Corporate Venture Capital to commercialize Pluristem’s PLX-PAD cell therapy product in Japan. However, there has been no further recent news from the company to explain last week’s rise in share price.
Pluristem Therapeutics gained 19.51 percent last week to finish at $1.47 per share.

Paratek

Paratek is a pharmaceutical company working on antibacterial therapeutics attempting to target infectious diseases.
Last week the company announced positive results from a Phase 3 clinical study of Omadacycline.
Paratek Therapeutics gained 16.75 percent last week to finish at $22.48 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went up 1.09 percent over the last five trading days and ended the week at 3,073.92 points. The Index is up 10.7 percent year-to-date.
Last week it was reported president Trump requested major cuts from medical research at NIH, this comes after he released a federal budget where he indicated cuts to the health agency. Blueprint Medicines is raising $150 million for their trials.
Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

• Athersys (NASDAQ:ATHX)
• Impax Laboratories (NASDAQ:IPXL)
• Adaptimmune Therapeutics (NASDAQ:ADAP)
• Sangamo Therapeutics (NASDAQ:SGMO)
• Karyopharm Therapeutics (NASDAQ:KPTI)

Athersys

This clinical-stage biotechnology company is focused on developing therapies in the space of regenerative medicine. Recently the company announced it would be presenting a corporate overview at the annual Needham Healthcare conference.
However, there has been no further recent news from the company to explain last week’s rise in share price.
Athersys gained 50 percent over the five-day trading week and ended at $1.71 per share.

Impax Laboratories

Impax is a specialty pharmaceutical developing generic products and branded ones. Last week the company received a favorable ruling regarding the patent validity for their nasal spray Zomig.
Impax Laboratories gained 36.76 percent over the five-day trading week and ended at $12.65 per share.

Adaptimmune Therapeutics

Adaptimmune is working on T-cell therapy to treat cancer through the use of their proprietary platform SPEAR. Last week Adaptimmune sold 15,700,223 American depositary shares at a price to the public of $4.20 per ADS.
The company gained 28.74 percent over the five-day trading week and ended at $5.51 per share.

Sangamo Therapeutics

This clinical stage biotechnology company seeks new therapies through the use of gene editing technology. Recently the company announced it would be presenting new data on the first-seen reduction of tau mRNA in a mouse model of Alzheimer’s disease.
Sangamo Therapeutics gained 26.83 percent over the five-day trading week and ended at $5.20 per share.

Karyopharm Therapeutics

Karyopharm is a clinical-stage pharmaceutical developing a drug against cancer. Last week the FDA lifted a clinical hold on trials for selinexor, a tumor suppressor, and enabled patient enrollment.
Karyopharm Therapeutics gained 22.52 percent over the five-day trading week and ended at $12.84 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was down 1.62 percent over the last five trading days and ended the week at 3,036.19 points. The Index is up 9.5 percent year-to-date.
Last week Republicans turned down President Trump and House Speaker Paul Ryan’s plan to repeal and replace Obamacare with a new health care bill. Ultragenyx Pharmaceutical failed a trial for a rare genetic disorder, sending its stock price down.
Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

• Nektar Therapeutics (NASDAQ:NKTR)
• Idera Pharmaceuticals (NASDAQ:IDRA)
• Ekso Bionics Holdings (NASDAQ:EKSO)
• Pulmatrix (NASDAQ:PULM)
• OraSure Technologies (NASDAQ:OSUR)

Nektar Therapeutics

This clinical-stage biopharmaceutical has a pipeline of products involved in treatment for areas like cancer, autoimmune diseases, and chronic pain. The company announced positive results from NKTR-181, an opioid analgesic set to be non-addictive.
Nektar Therapeutics gained 44.71 percent over the five-day trading week and ended at $22.42 per share.

Idera Pharmaceuticals

Idera seeks to treat cancers and rare diseases like melanoma and dermatomyositis. The company recently posted its fourth quarter and 2016 financial results, where it claimed they would be looking into researching the full potential of one of their lead products IMO-2125. However, there has been no further recent news from the company to explain last week’s rise in share price.
Idera Pharmaceuticals gained 20.39 percent over the five-day trading week and ended at $2.48 per share.

Ekso Bionics

This company develops robotic exoskeletons to help patients recovering from injuries by promoting mobility and help correct the posture of the user. Last week the company appointed a new board member a healthcare veteran Howard Palefsky. However, there has been no further recent news from the company to explain last week’s rise in share price.
Ekso Bionics gained 17.48 percent over the five-day trading week and ended at $3.84 per share.

Pulmatrix

This biotechnology company seeks to create therapies to treat chronic respiratory diseases. Last week the company received a patent in Europe for its iSPERSE inhaled drug technology.
Pulmatrix gained 14.56 percent over the five-day trading week and ended at $3.54 per share.

OraSure Technologies

OraSure is working on developing medical devices designed to detect or diagnose critical medical conditions. The company was listed in the S&P SmallCap 600 (INDEXSP:SP600) last week.
OraSure Technologies gained 11.69 percent over the five-day trading week and ended at $12.13 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.